First presentations of Bimzelx (bimekizumab) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 – UCB
UCB, announced the first presentation of two-year data from the Phase III studies, BE MOBILE 1 and BE MOBILE 2, and the open-label extension, BE MOVING, evaluating bimekizumab,… read more.
